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ABSTRACT
Objective: To derive and validate a set of clinical risk
prediction algorithm to estimate the 10-year risk of 11
common cancers.
Design: Prospective open cohort study using routinely
collected data from 753 QResearch general practices in
England. We used 565 practices to develop the scores
and 188 for validation.
Subjects: 4.96 million patients aged 25–84 years in the
derivation cohort; 1.64 million in the validation cohort.
Patients were free of the relevant cancer at baseline.
Methods: Cox proportional hazards models in the
derivation cohort to derive 10-year risk algorithms. Risk
factors considered included age, ethnicity, deprivation,
body mass index, smoking, alcohol, previous cancer
diagnoses, family history of cancer, relevant comorbidities
and medication. Measures of calibration and
discrimination in the validation cohort.
Outcomes: Incident cases of blood, breast, bowel,
gastro-oesophageal, lung, oral, ovarian, pancreas,
prostate, renal tract and uterine cancers. Cancers were
recorded on any one of four linked data sources (general
practitioner (GP), mortality, hospital or cancer records).
Results:We identified 228 241 incident cases during
follow-up of the 11 types of cancer. Of these 25 444 were
blood; 41 315 breast; 32 626 bowel, 12 808 gastro-
oesophageal; 32 187 lung; 4811 oral; 6635 ovarian; 7119
pancreatic; 35 256 prostate; 23 091 renal tract; 6949
uterine cancers. The lung cancer algorithm had the best
performance with an R2 of 64.2%; D statistic of 2.74;
receiver operating characteristic curve statistic of 0.91 in
women. The sensitivity for the top 10% of women at
highest risk of lung cancer was 67%. Performance of the
algorithms in men was very similar to that for women.
Conclusions:We have developed and validated a
prediction models to quantify absolute risk of 11
common cancers. They can be used to identify
patients at high risk of cancers for prevention or further
assessment. The algorithms could be integrated into
clinical computer systems and used to identify high-risk
patients.
Web calculator: There is a simple web calculator to
implement the Qcancer 10 year risk algorithm together
with the open source software for download (available at
http://qcancer.org/10yr/).
INTRODUCTION
The UK has one of the worst records for
cancer in Europe with late diagnoses and
poor survival.1 Each year around 230 000
people in England are diagnosed with
cancer and around 125 000 die from it.2 The
early diagnosis and prevention of cancer is
likely to remain a high priority especially
with the global decline in other major causes
of mortality such as cardiovascular disease
and the ageing population.
Over the past few years, we developed and
validated a series of risk prediction algorithms
collectively known as the QCancer algo-
rithms.3–10 These were designed to quantify
the absolute risk that a patient has an existing
cancer based on combinations of symptoms
and readily available risk factors and are
intended to help inform decisions regarding
further investigation and referral.3–10 We
decided to build on this work and derive a
Strengths and limitations of this study
▪ The QCancer-10 year risk algorithms provide
valid measures of absolute risk in the general
population of patients as shown by the perform-
ance in a separate validation cohort.
▪ Key strengths include size, duration of follow up,
representativeness, and lack of selection, recall
and respondent bias.
▪ The study has good face validity since it has
been conducted in the setting where the majority
of patients in the UK are assessed, treated and
followed up.
▪ The study used linked hospital, mortality and
cancer records and is therefore likely to have
picked up the majority of cancer diagnoses.
▪ The algorithms do not include some potential
risk factors for cancer such as diet or physical
activity since these are not routinely recorded in
electronic health records.
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set of risk prediction algorithms to quantify absolute risk
of future cancer over a 10-year period using predictor
variables recorded in the patient’s primary care elec-
tronic record. In particular, we were interested to quan-
tify the absolute risk of cancer in (1) patients with a
positive family history of speciﬁc cancers, previous
cancers or a chronic disease which might increase
cancer risk and might require additional surveillance
and (2) those with potentially modiﬁable risk factors
(such as smoking and alcohol) for whom quantiﬁcation
of absolute risk might be useful to support efforts to
lower risk. We decided to focus on the 11 most com-
monly occurring cancers in men and women in
England. This paper reports the results of the derivation
and validation of the new algorithms based on the
QResearch database linked to cancer registrations, mor-
tality and hospital episode statistics.
METHODS
Study design and data source
We undertook a prospective cohort study in a large
population of primary care patients from an open
cohort study using the QResearch database (V.38).
The QResearch database is a large pseudonymised
database of electronic health records from over 750
general practices in the UK which has been described in
detail elsewhere (http://www.qresearch.org). Over 99%
of people in the UK are registered with general practices
and have information routinely recorded on an ongoing
basis when they consult their general practitioner (GP)
or other primary care professional, receive prescriptions
and from referrals to secondary care. The database
includes event level detailed information on patient
demographics (year of birth, sex, ethnicity, deprivation),
medication, clinical diagnoses, referrals, clinical values
(such as body mass index (BMI), systolic blood pres-
sure), laboratory investigations. The QResearch database
has data from primary care dating back to 1989 which
has been linked at individual patient level to cancer
registrations data (from 1990 onwards), mortality
records (from 1997 onwards) and to hospital admissions
data (from 1998 onwards). It has a population which is
representative of that in UK and the database has been
used extensively for epidemiological research including
disease-based epidemiology, health services research, the
development of risk prediction models and evaluation
of drug safety.
We included all practices in England who had been
using their Egton Medical Information Systems (EMIS)
computer system for at least a year. We randomly allo-
cated three-quarters of practices to the derivation data
set and the remaining quarter to a validation data set.
We identiﬁed an open cohort of patients aged
25–84 years drawn from patients registered with practices
between 1 January 1998 and 30 September 2013. We
excluded patients who did not have a postcode-related
Townsend score. For each type of cancer, we excluded
patients with a history of the relevant cancer any time
prior to the study start date. We determined an initial
entry date to the cohort for each patient, which was the
latest of the following dates: 25th birthday, date of regis-
tration with the practice plus 1 year, date on which the
practice computer system was installed plus 1 year, and
the beginning of the study period (1 January 1998).
Patients were censored at the earliest date of the diagno-
sis of cancer, death, deregistration with the practice,
last upload of computerised data, or the study end date
(1 October 2013).
Cancer outcomes
Our outcomes were incident diagnosis of each type of
cancer focusing on the 11 most common cancers in
England in 2012 (excluding skin cancers) as identiﬁed
by the Ofﬁce of National Statistics (ONS).11 The cancers
were as follows (listed alphabetically):
1. Blood cancers (including leukaemias, Hodgkins
lymphomas, non-Hodgkins lymphoma, myeloma)
2. Bowel cancer (including colon and rectal cancer)
3. Breast cancer (women only)
4. Gastro-oesophageal cancer
5. Lung cancer
6. Oral cancer
7. Ovarian cancer (women only)
8. Pancreatic cancer
9. Prostate cancer (men only)
10. Renal tract cancer (bladder or kidney)
11. Uterine cancer (women only).
We included cancer cases diagnosed on any of the
four linked data sources (1) patients GP record (2) on
their linked mortality record (3) hospital record or
(4) cancer registry record. We used the earliest recorded
date of cancer diagnosis on any of the four data sources
as the index date.
The QResearch database is linked at individual patient
level to the hospital admissions data, the Ofﬁce for
National Statistics mortality records and the Ofﬁce for
National Statistics Cancer Registry using a project spe-
ciﬁc pseudonymised National Health Service (NHS)
number. The recording of NHS numbers is valid and
complete for 99.8% of QResearch patients, 99.9% for
ONS mortality and cancer records and 98% for hospital
admissions records.12 13 We deﬁned patients as having
the cancer of interest if there was a record of the rele-
vant clinical code either in their GP record, their linked
hospital record, their linked mortality record or their
linked cancer registry record.
We used Read codes to identify cancer cases from the
GP record. We used International Classiﬁcation of
Diseases 10th Edition (ICD 10) clinical codes to identify
cancer cases from hospital, cancer registry and mortality
records except for the period of 3 years between
1 January 1998 and 31 December 2000 where ICD 9
was in use for mortality records. Web extra table 1 lists
all the clinical codes used to identify each cancer
outcome.
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Risk factors
We examined the following predictor variables based on
established risk factors for each cancer as determined in
other studies14–17 or listed on the Cancer Research UK
website.18 We focused on variables which are likely to be
recorded in the patient’s electronic record and which
the patient is likely to know.
Variables tested for all outcomes
The following variables were considered for all cancer
outcomes:
▸ Age at baseline (continuous, ranging from 25 to
84 years)
▸ BMI (continuous)
▸ Smoking status (non-smoker; ex; light (1–9 cigar-
ettes/day); moderate (10–19 cigarettes/day); heavy
smoker (20+ cigarettes/day)
▸ Alcohol use (none, trivial (<1 unit/day); light (1–
2 units/day); moderate (3–6 units/day); heavy (7–
9 units/day); very heavy (>9 units/day))
▸ Townsend deprivation score (continuous)
▸ Ethnic group (White/not recorded, Indian, Pakistani,
Bangladeshi, Other Asian, Caribbean, Black African,
Chinese, Other)
▸ Type 1 diabetes
▸ Type 2 diabetes
▸ Manic depression or schizophrenia
▸ Use of antipsychotics at baseline
▸ Use of hormone replacement therapy (HRT, women)
at baseline (progesterone only, oestrogen only; com-
bined preparation; no HRT)
▸ Use of oral contraceptive (women) at baseline
▸ Previous diagnoses of cancer at baseline apart from
the incident one under consideration recorded in
the GP record. We included diagnoses of the follow-
ing cancers as separate predictors for each cancer
outcome—blood, bowel, brain, breast (in women),
cervical (in women), gastro-oesophageal, lung, oral,
ovarian (in women), pancreatic, prostate (in men),
renal tract, uterine (in women).
Each type of previous cancer was considered as a sep-
arate predictor for each outcome.
Variables tested for specific cancers
Additional risk factors for individual cancer outcomes
included:
▸ Blood cancers: family history of blood cancers
▸ Bowel cancer: family history of bowel cancer; ulcerative
colitis; past colonic polyps
▸ Breast cancer: family history of breast cancer; family history
of gynaecological cancer; benign breast disease (ﬁbro-
cystic disease, intraductal papilloma, ﬁbroadenoma)
▸ Gastro-oesophageal cancer: family history of bowel
cancer; Barratt’s oesophagus; peptic ulcer
▸ Lung cancer: family history of lung cancer; asbestos expos-
ure; asthma; chronic obstructive pulmonary disease
▸ Ovarian cancer: family history of ovarian cancer; poly-
cystic ovarian disease; endometriosis
▸ Pancreatic cancer: chronic pancreatitis; peptic ulcer
▸ Prostate cancer: family history of prostate cancer
▸ Renal tract cancer: family history of renal cancer; renal
stones
▸ Uterine cancer: family history of gynaecological cancer;
polycystic ovarian disease; endometriosis; ﬁbroids;
endometrial polyps or endometrial hyperplasia.
BMI, smoking status and alcohol use were obtained
from values recorded closest to the baseline date and prior
to cancer diagnosis. All other risk factors were based on
the latest information recorded before entry to the cohort.
Use of antipsychotic medication at baseline was deﬁned as
at least two prescriptions with the most recent one within
28 days of the date of entry to the cohort. For HRT and
oral contraceptive use, the deﬁnition was at least two pre-
scriptions with the most recent one within 6 months of the
date of entry to the cohort since prescriptions are often
issued for 6 months at a time.
Derivation and validation of the models
We developed and validated the risk prediction algo-
rithms using established methods.10 19 20–22 We used
multiple imputation to replace missing values for BMI,
alcohol and smoking status and used these values in our
main analyses.23–26 We carried out ﬁve imputations. We
used Cox’s proportional hazards models to estimate the
coefﬁcients for each risk factor for men and women sep-
arately, using robust variance estimates to allow for the
clustering of patients within general practices. We used
Rubin’s rules to combine the results across the imputed
data sets.27 We used fractional polynomials28 to model
non-linear risk relationships with continuous variables
(age, BMI, Townsend deprivation score). We ﬁtted full
models initially and retained variables if they had a
hazard ratio (HR) of <0.90 or >1.10 (for binary vari-
ables) and were statistically signiﬁcant at the 0.01 level.
For previous diagnoses of cancer, we retained variables
which were signiﬁcant at the 0.05 level since some of the
cancers are rare. In order to simplify the models we
focused on variables for the most common conditions
and medications and combined similar variables with
comparable HRs where possible.
We examined interactions between predictor variables
and age (focusing on family history of cancer and
smoking status). We used the regression coefﬁcients for
each variable from the ﬁnal model as weights which we
combined with the baseline survivor function evaluated
for each month up to 15 years to derive risk equations
over a period of 15 years of follow-up.29 This enabled us
to derive risk estimates for each year of follow-up, with a
speciﬁc focus on 10-year risk estimates. We estimated the
baseline survivor function based on zero values of
centred continuous variables, with all binary predictor
values set to zero.
Validation of the models
We used multiple imputation in the validation cohort to
replace missing values for BMI, alcohol and smoking
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status. We carried out ﬁve imputations. We applied the
risk equations for men and women obtained from the
derivation cohort to the validation cohort and calculated
measures of discrimination. As in previous studies,30 we
calculated R2 (explained variation in time to cancer
diagnosis31), D statistic32 (a measure of discrimination
where higher values indicate better discrimination) and
the area under the receiver operating characteristic
curve (ROC statistic) at 10 years and combined these
across data sets using Rubin’s rules. We assessed calibra-
tion (comparing the mean predicted risks at 10 years
with the observed risk by tenth of predicted risk). The
observed risks were obtained using the Kaplan-Meier
estimate evaluated at 10 years. We applied the algorithms
to the validation cohort to deﬁne the thresholds for the
10% of patients at highest estimated risk of each cancer
at 10 years.
As an additional analysis we also calculated the valid-
ation statistics on the subset of the validation cohort
with no missing data for BMI, alcohol and smoking
status (a complete case analysis).
We used all the available data on the database to maxi-
mise the power and also generalisability of the results.
We used STATA (V.13) for all analyses.
RESULTS
Overall study population
Overall, 753 QResearch practices in England met our
inclusion criteria, of which 565 were randomly assigned
to the derivation data set with the remainder assigned to
a validation cohort. We identiﬁed 4 964 904 patients
aged 25–84 years in the derivation cohort. We excluded
21 139 patients (0.43%) without a recorded Townsend
score, leaving 4 943 765 for analysis. Table 1 shows
numbers with diagnoses of each previous cancer
excluded from the model for each type of cancer.
We identiﬁed 1 635 592 patients aged 25–84 years in
the QResearch validation cohort. We excluded 10 796
patients (0.66%) without a recorded Townsend score,
leaving 1 624 796 patients for the analysis. The numbers
of patients with previous cancer diagnoses in the valid-
ation cohort are shown in table 1.
Table 1 also shows the baseline characteristics of men
and women in the derivation and validation cohorts. For
example, in the derivation cohort, smoking status was
recorded in 94.1% of women, alcohol intake in 83.5%,
ethnicity in 61.1% and BMI in 84.4%. These values were
around 5% higher than recording levels in men and
were similar to corresponding values for men and
women in the validation cohort. As in previous
studies11 13 the patterns of missing data supported the
use of multiple imputation to replace missing values for
smoking status, alcohol intake and BMI.
Incidence rates of cancer
In the derivation cohort, we identiﬁed 228 241 incident
cases of the 11 types of cancer on one or more of the
four linked data sources during follow-up. Of these
25 444 were blood; 32 626 were bowel; 41 315 were
breast; 12 808 were gastro-oesophageal; 32 187 were
lung; 4811 were oral; 6635 were ovarian; 7119 were pan-
creatic; 35 256 were prostate cancer; 23 091 were renal
tract; 6949 were uterine.
Table 2 shows the numbers of cases and age standar-
dised incidence rates for each cancer in women in the
derivation cohort. There were a total of 110 555 cases of
the 10 types of cancer in women identiﬁed on one or
more of the four linked data sources (GP, hospital, mor-
tality or cancer registry). Of these, 79 863 (72.2%) were
ascertained from the GP record, 89 927 (81.3%) from
the GP or linked mortality record; 105 465 (95.4%)
from the GP, mortality or hospital record. The highest
ascertainment rate based on the GP record alone was
for breast cancer (86.8%) and the lowest was for uterine
cancer (47.4%).
Table 3 shows the corresponding ﬁgures for men. Of
the 117 686 cases of the eight cancer types in men
recorded on any of the four data sources, 84 787
(72.0%) were ascertained on the GP record, 95 933
(81.5%) from the GP or linked mortality record,
111 990 (95.2%) from the GP, mortality or hospital
record. Ascertainment based on the GP record alone
was highest for prostate cancer (85.1%) and lowest for
renal tract cancer (55.3%).
Predictor variables
Table 4 shows the adjusted HRs for the ﬁnal models for
seven cancers occurring in men and women (blood,
bowel, gastro-oesophageal, lung, oral, pancreas, renal
tract). Table 5 shows the adjusted HRs for three cancers
occurring in women (breast, ovary and uterus). Table 6
shows the adjusted HRs for prostate cancer. Figure 1
shows graphs of adjusted HRs from the fractional poly-
nomial terms for age for each cancer. Figure 2 shows
graphs of adjusted HRs from the fractional polynomial
terms for BMI for each cancer. Figure 3 shows graphs of
adjusted HRs for the fractional polynomial terms for
Townsend deprivation score for each cancer. Figure 4
shows graphs of the adjusted HRs for the interactions
between age and family history for each relevant cancer.
Figure 5 show graphs of the adjusted HRs for the inter-
actions between age and smoking status for each rele-
vant cancer.
The text below describes the models for women in
detail below though similar results were obtained for
men as shown in the relevant tables.
Blood cancer
There were seven variables in the ﬁnal model for
women for blood cancer. These were age, BMI (linear),
smoking status (33% higher risk in heavy smokers com-
pared with non-smokers), type 1 diabetes (51%
increased risk), family history of blood cancer (fourfold
higher risk), prior brain cancer (fourfold higher risk),
and prior ovarian cancer (59% increased risk). The ﬁnal
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Table 1 Baseline characteristics of patients in the derivation and validation cohorts aged 25–84 years
Derivation men
n (%)
Derivation women
n (%)
Validation men
n (%)
Validation women
n (%)
Total (years) 2 447 866 2 495 899 802 437 822 359
25–34 805 109 (32.9) 870 317 (34.9) 278 480 (34.7) 309 425 (37.6)
35–44 613 038 (25.0) 551 468 (22.1) 201 950 (25.2) 179 621 (21.8)
45–54 425 824 (17.4) 394 520 (15.8) 132 729 (16.5) 121 668 (14.8)
55–64 298 448 (12.2) 297 981 (11.9) 91 781 (11.4) 91 285 (11.1)
65–74 203 714 (8.3) 227 761 (9.1) 64 283 (8.0) 71 086 (8.6)
75+ 101 733 (4.2) 153 852 (6.2) 33 214 (4.1) 49 274 (6.0)
Mean age (SD) 44.3 (14.8) 44.9 (15.9) 43.8 (14.7) 44.1 (15.9)
Mean Townsend score (SD) 0.3 (3.6) 0.2 (3.6) 0.6 (3.6) 5 (3.5)
Body mass index recorded 1 903 519 (77.8) 2 105 539 (84.4) 621 882 (77.5) 691 753 (84.1)
Mean BMI (SD) 26.3 (4.2) 25.7 (5.0) 26.2 (4.1) 25.5 (5.0)
Ethnicity recorded 1 380 685 (56.4) 1 525 005 (61.1) 462 619 (57.7) 509 242 (61.9)
White/not recorded 2 231 641 (91.2) 2 271 520 (91.0) 725 421 (90.4) 743 043 (90.4)
Indian 42 771 (1.7) 37 773 (1.5) 13 192 (1.6) 12 376 (1.5)
Pakistani 22 004 (0.9) 16 893 (0.7) 8557 (1.1) 6436 (0.8)
Bangladeshi 17 169 (0.7) 13 170 (0.5) 5803 (0.7) 4235 (0.5)
Other Asian 24 494 (1.0) 27 750 (1.1) 7954 (1.0) 9034 (1.1)
Caribbean 18 553 (0.8) 23 920 (1.0) 6989 (0.9) 8691 (1.1)
Black African 37 003 (1.5) 40 742 (1.6) 14 911 (1.9) 15 729 (1.9)
Chinese 12 493 (0.5) 17 702 (0.7) 3564 (0.4) 5281 (0.6)
Other 41 738 (1.7) 46 429 (1.9) 16 046 (2.0) 17 534 (2.1)
Smoking recorded 2 188 935 (89.4) 2 349 027 (94.1) 715 821 (89.2) 774 509 (94.2)
Non-smoker 1 081 822 (44.2) 1 433 446 (57.4) 347 253 (43.3) 467 440 (56.8)
Ex-smoker 448 480 (18.3) 392 870 (15.7) 149 221 (18.6) 134 426 (16.3)
Light smoker (1–9 cigarettes/day) 351 559 (14.4) 284 482 (11.4) 117 904 (14.7) 96 014 (11.7)
Moderate smoker (10–19 Cigarettes/day) 167 089 (6.8) 152 115 (6.1) 55 987 (7.0) 49 627 (6.0)
Heavy smoker (20+ cigarettes /day) 139 985 (5.7) 86 114 (3.5) 45 456 (5.7) 27 002 (3.3)
Alcohol recorded 1 930 167 (78.9) 2 084 701 (83.5) 623 247 (77.7) 677 551 (82.4)
Non-drinker 433 515 (17.7) 753 150 (30.2) 137 452 (17.1) 238 102 (29.0)
Trivial drinker (<1 unit/day) 585 589 (23.9) 849 734 (34.0) 187 131 (23.3) 275 188 (33.5)
Light drinker (1–2 units/day) 358 713 (14.7) 295 009 (11.8) 118 697 (14.8) 101 967 (12.4)
Moderate drinker (3–6 units/day) 486 003 (19.9) 176 644 (7.1) 159 164 (19.8) 58 675 (7.1)
Heavy drinker (7–9 units/day) 41 223 (1.7) 5332 (0.2) 12 651 (1.6) 1782 (0.2)
Very heavy drinker (>9 units/day) 18 473 (0.8) 3743 (0.1) 5964 (0.7) 1446 (0.2)
Family history of cancer
Family history of lung cancer 13 967 (0.6) 17 453 (0.7) 4302 (0.5) 5366 (0.7)
Family history of bowel cancer 29 877 (1.2) 43 741 (1.8) 9346 (1.2) 13 343 (1.6)
Family history of renal cancer 2465 (0.1) 2767 (0.1) 952 (0.1) 1070 (0.1)
Family history of breast cancer NA 95 807 (3.8) NA 32 725 (4.0)
Family history of uterine cancer NA 2030 (0.1) NA 638 (0.1)
Family history of ovarian cancer NA 5412 (0.2) NA 1722 (0.2)
Family history of prostate cancer 4230 (0.2) NA 979 (0.1) NA
Prior diagnosis of cancer
Prior bowel cancer 4872 (0.2) 4330 (0.2) 1553 (0.2) 1370 (0.2)
Prior pancreatic cancer 143 (0.0) 140 (0.0) 57 (0.0) 47 (0.0)
Prior lung cancer 1488 (0.1) 977 (0.0) 485 (0.1) 293 (0.0)
Prior gastro-oesophageal cancer 976 (0.0) 562 (0.0) 303 (0.0) 134 (0.0)
Prior renal cancer 4069 (0.2) 1561 (0.1) 1263 (0.2) 499 (0.1)
Prior blood cancer 5953 (0.2) 4257 (0.2) 1906 (0.2) 1399 (0.2)
Prior oral cancer 964 (0.0) 571 (0.0) 315 (0.0) 215 (0.0)
Prior brain cancer 180 (0.0) 157 (0.0) 55 (0.0) 58 (0.0)
Prior breast cancer NA 25 108 (1.0) NA 7781 (0.9)
Prior uterine cancer NA 1987 (0.1) NA 669 (0.1)
Prior ovarian cancer NA 2242 (0.1) NA 725 (0.1)
Prior cervical cancer NA 3582 (0.1) NA 1194 (0.1)
Prior prostate cancer 7778 (0.3) NA 2518 (0.3) NA
Continued
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model for men was similar except that prior renal
cancer (46% increased risk) was a predictor instead of
prior brain cancer.
Bowel cancer
There were 12 variables in the ﬁnal model for bowel
cancer for women. These were age, ethnicity (lower risk
among non-white groups), smoking status (17% higher
risk in heavy smokers), alcohol (36% higher risk in heavy
drinkers), family history of bowel cancer (94% higher
risk at the mean age of 45), ulcerative colitis (75% higher
risk), colonic polyp (twofold higher risk), type2 diabetes
(16% higher risk), previous breast cancer (16% higher
risk), previous ovarian cancer (98% higher risk), previous
uterine cancer (61% higher risk), previous cervical
cancer (74% higher risk). There was an interaction
between family history of bowel cancer and age which
indicated higher HRs associated with a family history in
younger women compared with older women (ﬁgure 4).
The direction and magnitude of the HRs was similar
for men except for there were three types of prior cancer
which were signiﬁcant in men but not women (lung,
blood, oral). BMI and Townsend deprivation score were
also included as linear terms in the model for men.
Breast cancer
There were 13 variables in the ﬁnal model for breast
cancer. These were age, BMI, Townsend deprivation
score, ethnicity (lower risks in non-white ethnic
groups), alcohol (25% higher risk in heavy drinkers
compared with non-drinkers), family history of breast
cancer (93% higher risk at the mean age of 45 years),
benign breast disease (51% higher risk), oral contra-
ceptive pill (13% higher risk), oestrogen containing
HRT (18% higher risk), manic depression or schizo-
phrenia (16% higher risk), previous blood cancer
(57% higher risk), previous lung cancer (86% higher
risk), and previous ovarian cancer (42% higher risk).
Increasing deprivation was associated with a lower risk
of breast cancer (ﬁgure 3). There was an interaction
between family history of breast cancer and age which
indicated higher HRs associated with a family history of
breast cancer in younger women compared with older
women (ﬁgure 4).
Gastro-oesophageal cancer
There were 12 variables in the ﬁnal model for gastro-
oesophageal cancer in women. The 12 variables were
age, BMI, Townsend deprivation score, smoking status
(2.4-fold higher risk in heavy smokers), alcohol (trivial
alcohol use was associated with an 11% lower risk and
very heavy drinking with a twofold increased risk com-
pared with non-drinkers), Barratt’s oesophagus (3.8-fold
higher risk), peptic ulcer disease (29% higher risk), type
2 diabetes (33% higher risk), and, previous lung cancer
(2.3-fold higher risk), previous blood cancer (twofold
Table 1 Continued
Derivation men
n (%)
Derivation women
n (%)
Validation men
n (%)
Validation women
n (%)
Comorbidities
Type 1 diabetes 9095 (0.4) 7207 (0.3) 2926 (0.4) 2391 (0.3)
Type 2 diabetes 68 727 (2.8) 53 070 (2.1) 21 772 (2.7) 16 959 (2.1)
Barratt’s oesophagus 3611 (0.1) 1760 (0.1) 1083 (0.1) 543 (0.1)
Peptic ulcer disease 65 467 (2.7) 34 951 (1.4) 20 005 (2.5) 10 404 (1.3)
Ulcerative colitis 8956 (0.4) 8983 (0.4) 2923 (0.4) 2751 (0.3)
Chronic pancreatitis 2438 (0.1) 1701 (0.1) 818 (0.1) 512 (0.1)
Colonic polyp 3146 (0.1) 2447 (0.1) 1010 (0.1) 802 (0.1)
Exposure to asbestos 2960 (0.1) 341 (0.0) 885 (0.1) 89 (0.0)
Asthma 201 250 (8.2) 225 052 (9.0) 66 466 (8.3) 74 440 (9.1)
COPD 28 194 (1.2) 22 731 (0.9) 8929 (1.1) 7056 (0.9)
Renal stones 28 022 (1.1) 21 640 (0.9) 8511 (1.1) 6602 (0.8)
Manic depression/schizophrenia 18 455 (0.8) 17 100 (0.7) 6618 (0.8) 5927 (0.7)
Benign breast disease NA 78 762 (3.2) NA 24 157 (2.9)
Polycystic ovarian disease NA 31 196 (1.2) NA 10 914 (1.3)
Endometrial hyperplasia or endometrial
polyps
NA 29 107 (1.2) NA 9031 (1.1)
Uterine fibroids NA 39 075 (1.6) NA 12 265 (1.5)
Prescribed medication
HRT (oestrogen only) NA 159 516 (6.4) NA 48 521 (5.9)
HRT (progesterone only) NA 33 638 (1.3) NA 9721 (1.2)
HRT (combined) NA 56 096 (2.2) NA 17 119 (2.1)
Oral contraceptive NA 248 131 (9.9) NA 84 565 (10.3)
Tamoxifen NA 11 899 (0.5) NA 3805 (0.5)
Antipsychotics 33 562 (1.4) 61 595 (2.5) 10 805 (1.3) 18 926 (2.3)
BMI, body mass index; COPD, chronic obstructive pulmonary disease; HRT, hormone replacement therapy; NA, not applicable.
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Table 4 Adjusted HRs with 95% CIs for seven cancers which occur in men and women in the derivation cohort (blood,
bowel, gastro-oesophageal, lung, oral, pancreatic and renal)
Cancer type Adjusted HRs in women (95% CI) Adjusted HRs in men (95% CI)
Blood*
Smoking status
Non-smoker 1.00 1.00
Ex-smoker 1.01 (0.96 to 1.06) 1.02 (0.98 to 1.07)
Light smoker (1–9/day) 1.20 (1.12 to 1.28) 1.10 (1.05 to 1.17)
Moderate smoker (10–19/day) 1.22 (1.12 to 1.33) 1.17 (1.08 to 1.27)
Heavy smoker (20+/day) 1.33 (1.20 to 1.47) 1.23 (1.14 to 1.34)
Other baseline factors
Type 1 diabetes 1.51 (1.03 to 2.22) 1.61 (1.21 to 2.13)
Family history of blood cancer 4.08 (1.53 to 10.87) 3.92 (1.47 to 10.45)
Prior brain cancer 4.12 (1.03 to 16.49) NS
Prior ovarian cancer 1.59 (1.08 to 2.33) NA
Prior renal cancer NS 1.46 (1.18 to 1.80)
Bowel†
Ethnic group
White/not recorded 1.00 1.00
Indian 0.35 (0.25 to 0.49) 0.56 (0.44 to 0.70)
Pakistani 0.47 (0.28 to 0.78) 0.56 (0.38 to 0.81)
Bangladeshi 0.85 (0.54 to 1.34) 0.41 (0.25 to 0.69)
Other Asian 0.59 (0.40 to 0.89) 0.62 (0.44 to 0.87)
Caribbean 0.71 (0.56 to 0.90) 0.70 (0.57 to 0.86)
Black African 0.69 (0.49 to 0.99) 0.75 (0.55 to 1.03)
Chinese 0.61 (0.35 to 1.05) 0.81 (0.51 to 1.28)
Other 0.80 (0.62 to 1.03) 0.59 (0.45 to 0.77)
Smoking status
Non-smoker 1.00 1.00
Ex-smoker 1.07 (1.03 to 1.12) 1.06 (1.02 to 1.09)
Light smoker (1–9/day) 1.11 (1.04 to 1.17) 1.07 (1.01 to 1.13)
Moderate smoker (10–19/day) 1.21 (1.12 to 1.31) 1.03 (0.93 to 1.13)
Heavy smoker (20+/day) 1.17 (1.06 to 1.30) 1.13 (1.05 to 1.22)
Alcohol
Non-drinker 1.00 1.00
Trivial drinker (<1 unit/day) 1.02 (0.98 to 1.06) 1.05 (1.00 to 1.10)
Light drinker (1–2 units/day) 1.05 (1.00 to 1.11) 1.14 (1.08 to 1.20)
Moderate drinker (3–6 units/day) 1.08 (1.01 to 1.16) 1.30 (1.24 to 1.36)
Heavy drinker (7–9 units/day) 1.38 (1.00 to 1.90) 1.62 (1.47 to 1.79)
Very heavy drinker (>9 units/day) 1.36 (0.80 to 2.32) 1.56 (1.33 to 1.83)
Other baseline factors
Family history of bowel cancer 1.94 (1.62 to 2.32)‡ 2.18 (1.84 to 2.59)‡
Ulcerative colitis 1.75 (1.48 to 2.08) 1.83 (1.58 to 2.11)
Colonic polyp 2.11 (1.62 to 2.76) 1.51 (1.19 to 1.90)
Type 2 diabetes 1.16 (1.07 to 1.26) 1.27 (1.20 to 1.35)
Prior breast cancer 1.16 (1.05 to 1.29) NA
Prior uterine cancer 1.61 (1.24 to 2.11) NA
Prior ovarian cancer 1.98 (1.48 to 2.65) NA
Prior cervical cancer 1.74 (1.36 to 2.21) NA
Prior lung cancer NS 1.87 (1.32 to 2.65)
Prior blood cancer NS 1.53 (1.26 to 1.87)
Prior oral cancer NS 1.62 (1.06 to 2.49)
Gastro-oesophageal§
Smoking status
Non-smoker 1.00 1.00
Ex-smoker 1.09 (0.99 to 1.19) 1.25 (1.18 to 1.32)
Light smoker (1–9/day) 1.78 (1.62 to 1.96) 1.73 (1.61 to 1.85)
Moderate smoker (10–19/day) 2.05 (1.82 to 2.31) 1.85 (1.68 to 2.04)
Heavy smoker (20+/day) 2.40 (2.08 to 2.78) 1.91 (1.73 to 2.11)
Continued
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Table 4 Continued
Cancer type Adjusted HRs in women (95% CI) Adjusted HRs in men (95% CI)
Alcohol
Non-drinker 1.00 1.00
Trivial drinker (<1 unit/day) 0.89 (0.83 to 0.96) 0.94 (0.88 to 1.00)
Light drinker (1–2 units/day) 0.91 (0.81 to 1.02) 0.89 (0.83 to 0.95)
Moderate drinker (3–6 units/day) 0.98 (0.86 to 1.11) 0.94 (0.88 to 1.00)
Heavy drinker (7–9 units/day) 2.00 (1.28 to 3.13) 1.24 (1.08 to 1.41)
Very heavy drinker (>9 units/day) 2.00 (0.99 to 4.01) 1.63 (1.33 to 1.98)
Other baseline factors
Barratt’s oesophagus 3.83 (2.63 to 5.57) 4.05 (3.30 to 4.97)
Peptic ulcer disease 1.29 (1.12 to 1.49) 1.25 (1.15 to 1.36)
Type 2 diabetes 1.33 (1.17 to 1.52) 1.18 (1.08 to 1.29)
Prior lung cancer 2.28 (1.02 to 5.08) NS
Prior blood cancer 2.14 (1.43 to 3.20) NS
Prior breast cancer 1.31 (1.09 to 1.56) NA
Prior oral cancer 3.84 (1.92 to 7.70) 2.65 (1.65 to 4.27)
Prior pancreatic cancer NS 4.16 (1.04 to 16.65)
Lung¶
Ethnic group
White/not recorded 1.00 1.00
Indian 0.54 (0.36 to 0.80) 0.36 (0.27 to 0.48)
Pakistani 0.37 (0.16 to 0.82) 0.40 (0.27 to 0.60)
Bangladeshi 1.18 (0.74 to 1.87) 0.84 (0.65 to 1.10)
Other Asian 0.69 (0.43 to 1.10) 0.36 (0.24 to 0.57)
Caribbean 0.52 (0.37 to 0.71) 0.58 (0.47 to 0.71)
Black African 0.55 (0.32 to 0.95) 0.45 (0.29 to 0.69)
Chinese 1.16 (0.69 to 1.96) 0.64 (0.40 to 1.03)
Other 0.62 (0.45 to 0.85) 0.51 (0.39 to 0.67)
Smoking status
Non-smoker 1.00 1.00
Ex-smoker 1.84 (1.60 to 2.13) 2.37 (2.04 to 2.76)
Light smoker (1–9/day) 5.67 (5.08 to 6.33) 5.93 (5.19 to 6.78)
Moderate smoker (10–19/day) 6.57 (5.84 to 7.40) 7.13 (6.15 to 8.27)
Heavy smoker (20+/day) 11.02 (9.84 to 12.33) 10.24 (8.94 to 11.74)
Alcohol
Non-drinker 1.00
Trivial drinker (<1 unit/day) NS 0.91 (0.87 to 0.95)
Light drinker (1–2 units/day) NS 0.92 (0.87 to 0.97)
Moderate drinker (3–6 units/day) NS 0.97 (0.93 to 1.02)
Heavy drinker (7–9 units/day) NS 1.13 (1.03 to 1.25)
Very heavy drinker (>9 units/day) NS 1.25 (1.09 to 1.43)
Other baseline factors
Family history of lung cancer 1.32 (1.10 to 1.58) 1.28 (1.08 to 1.52)
Asthma 1.33 (1.24 to 1.41) 1.18 (1.11 to 1.26)
Chronic obstructive pulmonary disease 1.97 (1.80 to 2.15) 1.92 (1.76 to 2.08)
Asbestos NS 1.85 (1.54 to 2.22)
Prior renal cancer 1.74 (1.31 to 2.31) 1.50 (1.30 to 1.74)
Prior blood cancer 1.93 (1.51 to 2.48) 1.91 (1.61 to 2.26)
Prior oral cancer 2.83 (1.76 to 4.56) 2.86 (2.15 to 3.80)
Prior breast cancer 1.53 (1.39 to 1.69) NA
Prior uterine cancer 1.53 (1.12 to 2.09) NA
Prior ovarian cancer 1.64 (1.17 to 2.29) NA
Prior cervical cancer 1.58 (1.26 to 1.97) NA
Prior bowel cancer NS 1.29 (1.09 to 1.52)
Prior gastro-oesophageal cancer NS 1.79 (1.28 to 2.49)
Oral**
Smoking status
Non-smoker 1.00 1.00
Ex-smoker 1.22 (1.06 to 1.41) 1.15 (1.04 to 1.28)
Continued
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Table 4 Continued
Cancer type Adjusted HRs in women (95% CI) Adjusted HRs in men (95% CI)
Light smoker (1–9/day) 2.12 (1.83 to 2.46) 2.31 (2.09 to 2.56)
Moderate smoker (10–19/day) 2.52 (2.11 to 3.00) 2.35 (2.04 to 2.70)
Heavy smoker (20+/day) 3.52 (2.86 to 4.33) 2.95 (2.60 to 3.35)
Alcohol
Non-drinker 1.00 1.00
Trivial drinker (<1 unit/day) 1.03 (0.91 to 1.16) 0.89 (0.79 to 1.00)
Light drinker (1–2 units/day) 1.18 (0.99 to 1.40) 1.02 (0.90 to 1.15)
Moderate drinker (3–6 units/day) 1.60 (1.35 to 1.90) 1.36 (1.22 to 1.53)
Heavy drinker (7–9 units/day) 2.86 (1.66 to 4.91) 2.59 (2.18 to 3.09)
Very heavy drinker (>9 units/day) 4.38 (2.25 to 8.52) 3.71 (2.99 to 4.59)
Other baseline factors
Prior blood cancer 4.54 (2.73 to 7.56) 2.34 (1.51 to 3.63)
Prior bowel cancer NS 1.62 (1.00 to 2.61)
Prior lung cancer NS 2.87 (1.29 to 6.40)
Prior ovarian cancer 4.14 (2.15 to 7.97) NA
Pancreas††
Smoking status
Non-smoker 1.00 1.00
Ex-smoker 1.03 (0.94 to 1.13) 1.09 (1.00 to 1.18)
Light smoker (1–9/day) 1.77 (1.59 to 1.97) 1.56 (1.41 to 1.73)
Moderate smoker (10–19/day) 1.89 (1.65 to 2.17) 1.96 (1.70 to 2.27)
Heavy smoker (20+/day) 2.02 (1.71 to 2.39) 1.94 (1.68 to 2.24)
Other baseline factors
Chronic pancreatitis 3.64 (2.11 to 6.28) 5.43 (3.72 to 7.94)
Type 2 diabetes 1.51 (1.31 to 1.74) 1.85 (1.65 to 2.07)
Prior renal cancer 1.97 (1.14 to 3.40) NS
Prior breast cancer 1.38 (1.13 to 1.67) NA
Prior blood cancer NS 1.71 (1.12 to 2.60)
Renal Tract‡‡
Smoking status
Non-smoker 1.00 1.00
Ex-smoker 1.27 (1.19 to 1.37) 1.23 (1.18 to 1.29)
Light smoker (1–9/day) 1.74 (1.61 to 1.89) 1.64 (1.56 to 1.72)
Moderate smoker (10–19/day) 2.23 (2.02 to 2.45) 2.05 (1.91 to 2.20)
Heavy smoker (20+/day) 2.35 (2.08 to 2.64) 2.24 (2.09 to 2.40)
Other baseline factors
Type 2 diabetes 1.34 (1.21 to 1.50) 1.21 (1.13 to 1.28)
Prior bowel cancer 1.44 (1.07 to 1.92) 1.25 (1.05 to 1.50)
Prior lung cancer NS 1.78 (1.23 to 2.58)
Prior prostate cancer NA 1.46 (1.26 to 1.68)
Prior blood cancer 1.63 (1.11 to 2.40) NS
Prior brain cancer 10.18 (3.28 to 31.58) NS
Prior uterine cancer 2.12 (1.51 to 2.98) NA
Prior ovarian cancer 2.62 (1.81 to 3.77) NA
Prior cervical cancer 2.56 (1.94 to 3.40) NA
For fractional polynomial terms and interactions see footnotes and figures 1–5.
*Blood cancer models also included age (2 FP terms) and body mass index (linear) in women and men.
†Bowel cancer models also included age (2 FP terms) and interaction between age and family history in women, and age (2 FP terms), BMI
(linear,positive), Townsend (linear, positive) and interaction between age and family history in men.
‡Adjusted HR evaluated at mean age.
§Gastro-oesophageal models also included age (2 FP terms), BMI (2 FP terms) and Townsend (linear, positive) in women and men.
¶Lung cancer models included age (2 FP terms), Townsend (2 FP terms) and BMI (2 FP terms) in women and men?
**Oral cancer models included age (1 FP term for women, 2 FP terms for men), Townsend (linear and positive in women and men) and BMI
(2 FP terms for men only).
††Pancreatic cancer models included age (1 FP term in women and men), BMI (linear for women, 2 FP terms for men) and Townsend (linear
and positive—women only).
‡‡Renal cancer models included age (2 FP terms in women and men), Townsend (2 FP terms women) and BMI (linear and positive in
women and men).
NA, not applicable; NS, not significant.
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higher risk), previous breast cancer (31% higher risk),
and previous oral cancer (3.8-fold higher risk).
The direction and magnitude of the HRs was similar
for men except for prior cancers where prior pancreatic
cancer was a signiﬁcant predictor for men not women
(fourfold higher risk) and prior lung and blood cancers
were signiﬁcant predictors in women but not in men.
Lung cancer
There were 15 variables in the ﬁnal model for lung
cancer in women. The 15 variables were age, BMI,
Townsend deprivation score (ﬁgure 3), ethnicity (lower
risk among non-white groups), smoking status, family
history of lung cancer (32% higher risk), asthma (33%
higher risk), chronic obstructive pulmonary disease
(97% higher risk), previous blood cancer (93% higher
risk), previous breast cancer (53% higher risk), previous
cervical cancer (58% higher risk), previous oral cancer
(2.8-fold higher risk), previous ovarian cancer (64%
higher risk), previous renal cancer (74% higher risk),
and previous uterine cancer (53% higher risk). There
was a ‘dose response’ association for risk of lung cancer
with smoking status—compared with a non-smoker: at
the mean age of 45 years, there was a 5.7-fold higher risk
for a light smoker; 6.6-fold higher risk for a moderate
smoker and an 11-fold higher risk for a heavy smoker.
Table 5 Adjusted HRs with 95% CIs for cancers
occurring in women in the derivation cohort (breast, ovary,
uterus)
Cancer type
Adjusted
HRs (95% CI)
Breast cancer*
Ethnic group
White/not recorded 1.00
Indian 0.73 (0.64 to 0.83)
Pakistani 0.71 (0.58 to 0.88)
Bangladeshi 0.39 (0.27 to 0.56)
Other Asian 0.78 (0.66 to 0.93)
Caribbean 0.82 (0.73 to 0.93)
Black African 0.75 (0.63 to 0.88)
Chinese 0.73 (0.56 to 0.94)
Other 0.83 (0.73 to 0.94)
Alcohol
Non-drinker 1.00
Trivial drinker (<1 unit/day) 1.05 (1.03 to 1.08)
Light drinker (1–2 units/day) 1.11 (1.07 to 1.15)
Moderate drinker (3–6 units/day) 1.21 (1.16 to 1.26)
Heavy drinker (7–9 units/day) 1.31 (1.07 to 1.61)
Very heavy drinker (>9 units/day) 1.25 (0.92 to 1.71)
Other baseline factors
Family history of breast cancer 1.93 (1.83 to 2.04)†
Benign breast disease 1.51 (1.45 to 1.57)
Current oral contraceptive 1.13 (1.07 to 1.20)
Current oestrogen containing HRT 1.18 (1.15 to 1.22)
Manic depression or schizophrenia 1.16 (1.04 to 1.30)
Prior lung cancer 1.86 (1.21 to 2.85)
Prior blood cancer 1.57 (1.31 to 1.88)
Prior ovarian cancer 1.42 (1.12 to 1.80)
Ovarian cancer‡
Family history of ovarian cancer 3.81 (2.72 to 5.33)†
Current oral contraceptive 0.65 (0.54 to 0.79)
Prior breast cancer 1.62 (1.41 to 1.88)
Prior cervical cancer 1.60 (1.08 to 2.38)
Uterine cancer§
Smoking status
Non-smoker 1.00
Ex-smoker 0.82 (0.77 to 0.87)
Light smoker (1–9/day) 0.83 (0.76 to 0.92)
Moderate smoker (10–19/day) 0.74 (0.65 to 0.84)
Heavy smoker (20+/day) 0.66 (0.56 to 0.77)
Other baseline factors
Manic depression or schizophrenia 1.55 (1.25 to 1.92)
Type 2 diabetes 1.35 (1.21 to 1.49)
Endometrial hyperplasia or polyp 2.35 (1.83 to 3.01)
Polycystic ovarian disease 1.98 (1.43 to 2.76)
Prior bowel cancer 1.56 (1.13 to 2.17)
Prior breast cancer 2.49 (2.22 to 2.79)
For fractional polynomial terms and interactions see footnotes and
figures 1–5.
*Breast cancer model also included terms for age (2 FP terms),
BMI (2 FP terms), Townsend (2 FP terms) and interaction
between age and family history.
†Adjusted HR evaluated at mean age in women.
‡Ovarian cancer model also included terms for age (2 FP terms),
BMI (linear and positive), and interaction between age and family
history.
§Uterine cancer model also included terms for age (2 FP terms),
and BMI (1 FP term).
HRT, hormone replacement therapy.
Table 6 Adjusted HRs with 95% CIs for prostate cancer
in men in the derivation cohort
Prostate cancer*
Adjusted
HR (95% CI)
Ethnic group
White/not recorded 1.00
Indian 0.60 (0.51 to 0.71)
Pakistani 0.42 (0.30 to 0.58)
Bangladeshi 0.29 (0.18 to 0.47)
Other Asian 0.46 (0.34 to 0.62)
Caribbean 2.84 (2.61 to 3.09)
Black African 1.98 (1.69 to 2.33)
Chinese 0.50 (0.32 to 0.76)
Other 1.48 (1.30 to 1.69)
Smoking status
Non-smoker 1.00
Ex-smoker 1.02 (0.92 to 1.12)†
Light smoker (1–9/day) 0.78 (0.70 to 0.87)†
Moderate smoker (10–19/day) 0.74 (0.63 to 0.87)†
Heavy smoker (20+/day) 0.79 (0.68 to 0.91)†
Other baseline factors
Family history of prostate cancer 7.65 (6.11 to 9.57)†
Manic depression or schizophrenia 0.64 (0.54 to 0.77)
Type 1 diabetes 0.57 (0.40 to 0.81)
Type 2 diabetes 0.90 (0.85 to 0.94)
For fractional polynomial terms and interactions see footnotes and
figures 1–5.
*Prostate cancer model also included terms for age (2 FP terms),
BMI (2 FP terms), Townsend (linear and negative) and
interactions between age and family history and age and smoking
status.
†Adjusted HR evaluated at mean age.
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There was also an interaction between smoking status
and age (ﬁgure 5) such that the ‘dose response’ effect
was most marked in women aged 60–70.
The direction and magnitude of the HRs was similar
for men except that three additional variables reached
signiﬁcance and were included in the ﬁnal model
(alcohol, prior bowel and gastro-oesophageal cancers).
Oral cancer
There were six variables in the ﬁnal model for oral
cancer in women. These were age, Townsend depriv-
ation score, smoking status (3.5-fold higher risk for
heavy smokers) alcohol (4.4-fold higher risk for very
heavy drinkers), previous blood cancer (4.5-fold higher
risk) and previous ovarian cancer (4.1-fold higher risk).
The direction and magnitude of the HRs was similar
for men except BMI, prior bowel and prior lung cancer
were signiﬁcant and so were included in the ﬁnal model
for men but not women.
Ovarian cancer
There were six variables in the ﬁnal model for ovarian
cancer which were age, BMI, family history of ovarian
cancer (3.8-fold higher risk at the mean age of
45 years), oral contraceptive use (35% reduced risk),
previous breast cancer (62% higher risk) and previous
cervical cancer (60% higher risk). There was an
interaction between age and family history as shown in
(ﬁgure 4) with higher HRs at both extremes of age.
Pancreatic cancer
There were eight variables in the ﬁnal model for pancre-
atic cancer in women. These were age, BMI, Townsend
score, smoking status (twofold higher risk in heavy
smokers), chronic pancreatitis (3.6-fold higher risk),
type 2 diabetes (51% higher risk), previous breast
cancer (38% higher risk) and previous renal cancer
(97% higher risk).
The direction and magnitude of the HRs was similar
for men except prior blood cancer reached signiﬁcance
and prior renal cancer did not.
Renal tract cancer
There were 11 variables in the ﬁnal model for renal
tract cancer in women. These were age, Townsend
deprivation score, BMI, smoking status (2.4-fold higher
risk in heavy smokers), type 2 diabetes (34% higher
risk), previous blood cancer (63% higher risk), previous
brain cancer (10-fold higher risk), previous cervical
cancer (2.6-fold higher risk), previous bowel cancer
(44% higher risk), previous ovarian cancer (2.6-fold
higher risk), previous uterine cancer (2.1-fold higher
risk). Increasing deprivation was associated with a lower
risk as shown in ﬁgure 3.
Figure 1 Showing graphs of the adjusted HRs for the fractional polynomial terms for age for each cancer.
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The direction and magnitude of the HRs was similar
for men except Townsend score was not signiﬁcant. Also
prior lung cancer and prostate cancer were signiﬁcantly
associated with increased risk of renal cancer but prior
blood cancer and brain cancer were not.
Uterine cancer
There were nine variables in the ﬁnal model for uterine
cancer. These were age, BMI, smoking status (heavy
smokers had a 34% lower risk), manic depression or
schizophrenia (55% higher risk), type 2 diabetes (35%
higher risk), endometrial hyperplasia or polyp (2.4-fold
higher risk), polycystic ovarian syndrome (98% higher
risk), previous breast cancer (2.5-fold higher risk) and
previous bowel cancer (56% higher risk).
Prostate cancer
There were nine variables in the ﬁnal model for prostate
cancer. These were age, BMI, Townsend deprivation
score, ethnicity, smoking status (reduced risks in current
smokers at the mean age of 44 years), family history of
prostate cancer (7.7-fold higher risk at the mean age of
44 years), manic depression/schizophrenia (36% lower
risk), type 1 diabetes (43% lower risk) and type 2 dia-
betes (10% lower risk). There were marked differences
in risk between different ethnic groups with the South
Asian and Chinese men having the lowest risks and
Black African and Caribbean men having the highest
risks. Caribbean men had a 2.8-fold higher risk of pros-
tate cancer than White men.
Figures 1 and 2 show the adjusted HRs for the frac-
tional polynomial terms for age and BMI. Figure 4
shows the HRs for the interaction between age and
family history of prostate cancer where HRs for family
history are highest among men under the age of 30.
Figure 5 shows the interaction between age and smoking
status—at younger ages heavy smoking is associated with
around a fourfold to ﬁvefold increased risk of prostate
cancer then the HRs decrease with advancing age.
Risk of incident cancers in patients with prior cancers
Table 7 summarises the adjusted HRs for each type of
cancer associated with different types of prior cancer at
baseline. For example, women with an existing diagnosis
of breast cancer have a signiﬁcantly increased risk of
bowel cancer (16% higher), lung cancer (53% higher),
pancreatic cancer (38% higher), gastro-oesophageal
cancer (31% higher), ovarian cancer (62% higher) and
uterine cancer (2.5-fold higher). Men with an existing
diagnosis of blood cancer have a signiﬁcantly increased
risk of bowel cancer (53% higher), lung cancer (91%
higher), oral cancer (2.3-fold higher) and pancreatic
cancer (71% higher). The other associations are shown
in table 7.
Figure 2 Showing graphs of the adjusted HRs for the fractional polynomial terms for body mass index for each cancer.
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Validation
Discrimination
Table 8 shows the performance of each algorithm in the
validation cohort for women and men. The lung cancer
algorithm had the highest values for all three perform-
ance measures evaluated over 10 years in men and
women—the algorithm explained 64.2% of the variation
in time to cancer diagnosis in women (R2), the D statis-
tic was 2.74 and the ROC value was 0.91. Apart from
breast cancer and ovarian cancer, the ROC values for all
the other algorithms exceeded 0.8 in men and women.
The algorithm for breast cancer had the lowest values
with an R2 value of 22.0%, D statistic of 1.09 and ROC
value of 0.76. The performance of the algorithm for
ovarian cancer was marginally better than that for breast
cancer with an R2 value of 29.1%, D statistic of 1.31 and
ROC value of 0.77.
Performance of the algorithms in men was very similar
to that for women. For prostate cancer, the performance
was good with an R2 of 54.8%, D statistic of 2.25 and ROC
value of 0.89. The algorithm for oral cancer had the
lowest performance among men although the R2 was
45.8%, D statistic was 1.88 and ROC value was 0.81.
Web extra table 2 shows the performance statistics
based on the 1 197 426 (73.7%) of patients in the valid-
ation cohort with complete data for BMI, smoking status
and alcohol use rather than using imputed values for
missing data. The results are similar though the absolute
values tend to be marginally lower than the analyses
based on imputed data.
Thresholds
Table 9 shows the classiﬁcation statistics of each algo-
rithm in the full validation cohort for the 10% of
women at highest predicted risk of each cancer. For
example, for the 10% of women at highest predicted
risk of lung cancer (ie, those with a 10-year predicted
risk score of 1.43% or higher), the sensitivity was 67.3%
and the observed risk at 10 years was 3.9%. For breast
cancer, the corresponding sensitivity was 27.5% with an
observed risk of 4.4% at 10 years for the top 10% of
women at highest predicted risk. Table 10 shows the cor-
responding results for men. For prostate cancer, for the
top 10% of men at highest predicted risk (a 10-year pre-
dicted risk score of 5.89% or higher) the sensitivity was
56% and the observed risk at 10 years was 8.4%.
Calibration
Figure 6 shows the mean predicted risks and the observed
risks at 10 years within each tenth of predicted risk in
order to assess the calibration of the model in women in
the validation cohort. Figure 7 shows the corresponding
calibration graph for men. There was close correspond-
ence between the mean predicted risks and the observed
risks within each model tenth in women and men indicat-
ing that the algorithms were well calibrated.
Figure 3 Showing graphs of the adjusted HRs for fractional polynomial terms for Townsend deprivation score for each cancer.
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Figure 8 shows the web calculator for an example
patient which is a 64-year-old man who is a heavy
smoker, has type 2 diabetes and a family history of bowel
cancer. His 10-year predicted risks of the following
cancers are: blood cancer (2%) bowel cancer (5.8%),
gastro-oesophageal cancer (3.3%) lung cancer (9.4%),
oral cancer (2%), renal cancer (4.6%), pancreatic
cancer (1.3%), prostate cancer (3.9%).
DISCUSSION
Summary of key findings
We have developed and validated a series of risk predic-
tion algorithms—collectively known as the QCancer
10 year risk algorithms—to quantify future absolute risk
of 10 common cancers in women and eight common
cancers in men. The algorithms incorporate predictor
variables which are associated with risk of cancer includ-
ing sociodemographic variables, lifestyle, morbidity,
medications, family history and previous diagnoses of
other cancers. The algorithms can be applied to any
adult aged 25–84 years in a primary care setting regard-
less of whether they have had a prior cancer. For nine of
the 11 cancers, the ROC values exceeded 0.8 which is
generally considered to be very good. For two of the
cancers in women (breast and ovarian) the ROC values
were lower at 0.76 and 0.77 though this is still consid-
ered acceptable.
The QCancer 10 year risk algorithms are designed to
quantify future risk of cancer and differ from the existing
QCancer algorithms3–10 which combine symptoms such
as appetite loss and abdominal pain with risk factors to
quantity the absolute risk that a patient has an existing
cancer as yet undiagnosed to help inform the decision
for further diagnostic tests. These algorithms to predict
existing cancer are designed to be used when patients
present with symptoms that might be indicative of
cancer.
Comparisons with the literature
We included established predictor variables in our ana-
lysis and found that our HRs were similar in magnitude
and direction to those reported in other studies. This
increases the clinical face validity of the variables
included as predictors in the ﬁnal algorithms. We have
summarised the key relationships below from the per-
spective of the relevant set of risk factors (rather than
by each cancer as described in our results section
above).
Smoking and cancer risk
We found that smoking was associated with a signiﬁ-
cantly increased risk of seven cancers (blood, bowel,33
gastro-oesophageal,34 35 lung,36 oral,37 pancreatic38 39
and renal tract18) with some evidence of a ‘dose
Figure 4 Showing graphs of the adjusted HRs for the interactions between age and family history for each relevant cancer.
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response’ relationship with higher levels of smoking
associated with higher levels of risk. Smoking was asso-
ciated with a decreased risk of uterine cancer which is
consistent with other studies.40 We found no signiﬁcant
association between smoking and ovarian or breast
cancer. We found an interaction between age and
smoking for risk of prostate cancer. At younger ages
heavy smoking is associated with around a fourfold to
ﬁvefold increased risk of prostate cancer then the HRs
decrease with advancing age.
Alcohol and cancer risk
Alcohol intake was associated with an increased risk
of four cancers (oral,41 breast41 42 bowel,41 gastro-
oesophageal34 41 43) with a tendency for higher
volumes of alcohol consumption to be associated with
higher levels of cancer risk. We found no signiﬁcant
association between alcohol and lung cancer in women
but there was an association for men.
Family history and cancer risk
Family history was associated with a higher risk of six
cancers (prostate,44 breast45 46 bowel47 48 blood, lung49
and ovarian cancer50 51). The magnitude of the risk of
ovarian cancer associated with a family history of ovarian
cancer in this study was 3.8 fold higher at the mean age
which is similar to the threefold to fourfold higher risk
reported elsewhere.50 51
Hormonal treatments and cancer risk
There was a small increased risk of breast cancer with
oral contraceptive use52 and oestrogen containing
HRT.53 54 There was a decreased risk of ovarian cancer
associated with use of oral contraceptives in line with
other studies.55 56 There was no clear association
between use of the oral contraceptive pill or HRT for
the remaining cancers.
Comorbidities and cancer risk
Ulcerative colitis and previous colonic polyps were asso-
ciated with a higher risk of bowel cancer.57 58 Barratt’s
oesophagus was associated with a fourfold higher risk of
gastro-oesophageal cancer. This is consistent with, but
lower than the 11-fold increase in risk of adenocarcin-
oma of the oesophagus.59 Chronic pancreatitis was asso-
ciated with a higher risk of pancreatic cancer.60 We
found a higher risk of breast cancer among patients with
benign breast disease.61 Manic depression or schizophre-
nia was associated with a higher risk of uterine cancer
and a marginal higher risk of breast cancer and a
reduced risk of prostate cancer.62 There was a twofold
higher risk of uterine cancer with polycystic ovarian
disease in line with other studies.63
Diabetes and cancer risk
Type 1 diabetes was associated with a higher risk of
blood cancer. Type 2 diabetes was associated with a
Figure 5 Showing graphs of the adjusted HRs for the interactions between age and smoking status for each relevant cancer.
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higher risk of ﬁve cancers (bowel,64–67 gastro-
oesophageal,68 pancreatic,69 70 renal tract69 and uterine
cancer69 71). Both type 1 and type 2 diabetes were asso-
ciated with a reduced risk of prostate cancer in line with
previous studies.72 73
Ethnicity and cancer risk
Ethnic groups other than the white/not recorded group
tended to be associated with decreased risk of three
cancers (breast cancer, bowel cancer, lung cancer)
which is consistent with other studies.74 We found no sig-
niﬁcant association between ethnicity and risk of the
other cancers included in our study except for prostate
cancer where black African and Caribbean men had sig-
niﬁcantly higher risks compared with white men, and
South Asian and Chinese men had signiﬁcantly lower
risks. This is consistent with other studies examining risk
of prostate cancer among different ethnic groups.75
Prior cancers
We have identiﬁed and quantiﬁed a number of associa-
tions between previous cancers and risk of future cancer
by cancer type. We think our ﬁndings have reasonable
face validity as they are consistent with those reported
elsewhere76 77 and we have been able to adjust for
potential confounding variables. For example, we found
that a previous diagnosis of lung cancer in men was asso-
ciated with an increased risk of three cancers (oral,
bowel and renal tract).77 Also, we found that a previous
diagnosis of blood cancer in women was associated with
an increased risk of ﬁve cancers (lung, oral, renal tract,
gastro-oesophageal and breast cancer).77 78 Similarly we
found that prior breast cancer was associated with an
increased risk of six cancers (uterine, bowel, lung, pan-
creatic, gastro-oesophageal and ovarian cancer76 77). We
found that prior ovarian cancer was associated with an
increased risk of ﬁve cancers (bowel, lung, oral, renal
tract and breast). Some of the associations between
prior cancer and risk of future cancer may reﬂect
common aetiologies between different cancers not fully
adjusted for in our multivariate model (eg, lifestyle
factors or genetic predisposition). Alternatively some
may represent secondary cancers directly related to the
ﬁrst but which have not been correctly coded as metasta-
ses. It is important to note that apparent lack of associa-
tions between some types of prior cancer and future
cancer may reﬂect small numbers especially where spe-
ciﬁc cancers are rare and/or have a poor 5-year survival
(such as pancreatic cancer). Additional research would
be needed to determine the potential utility of
enhanced screening among patients with an existing
malignancy who are at increased risk of a second
primary cancer.
Thresholds
Generally we envisage that cancer risk prediction values
would be kept continuous for assessment of an individ-
ual although at some point there needs to be a cut-off if
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a clinician is going to take action for an individual
patient. At national level, policymakers and commis-
sioners tend to make recommendations around absolute
thresholds to ensure equitable access and consistent
management across a health community. This is already
common place for cardiovascular disease risk where the
latest National Institute for Health and Care Excellence
(NICE) guidelines from 2014 recommend treatment
with statins for patients with a 10-year cardiovascular
disease risk above 10%.79 However, in this paper, we
have not provided deﬁnite comment on what threshold
of absolute risk should be used to deﬁne ‘high risk’
Table 8 Performance of each algorithm in the validation cohort in men and women (including patients with imputed data)
Statistic Women: mean (95% CI) Men: mean (95% CI)
Blood cancer
D statistic 1.639 (1.578 to 1.699) 1.726 (1.673 to 1.78)
R2 (%) 39.1 (37.3 to 40.8) 41.6 (40.1 to 43.1)
ROC statistic 0.803 (0.796 to 0.811) 0.8 (0.793 to 0.807)
Breast cancer
D statistic 1.088 (1.058 to 1.119) NA
R2 (%) 22 (21.1 to 23) NA
ROC statistic 0.761 (0.758 to 0.765) NA
Bowel cancer
D statistic 1.974 (1.922 to 2.027) 2.139 (2.091 to 2.188)
R2 (%) 48.2 (46.9 to 49.5) 52.2 (51.1 to 53.3)
ROC statistic 0.847 (0.842 to 0.852) 0.862 (0.858 to 0.866)
Gastro-oesophageal cancer
D statistic 2.277 (2.181 to 2.372) 2.241 (2.174 to 2.308)
R2 (%) 55.3 (53.2 to 57.4) 54.5 (53 to 56)
ROC statistic 0.873 (0.864 to 0.881) 0.868 (0.862 to 0.874)
Lung cancer
D statistic 2.742 (2.687 to 2.797) 2.797 (2.75 to 2.844)
R2 (%) 64.2 (63.3 to 65.1) 65.1 (64.4 to 65.9)
ROC statistic 0.905 (0.901 to 0.91) 0.911 (0.908 to 0.914)
Oral cancer
D statistic 1.817 (1.67 to 1.964) 1.881 (1.771 to 1.991)
R2 (%) 44.1 (40.1 to 48.1) 45.8 (42.9 to 48.7)
ROC statistic 0.795 (0.775 to 0.814) 0.808 (0.794 to 0.823)
Ovarian cancer
D statistic 1.311 (1.237 to 1.385) NA
R2 (%) 29.1 (26.8 to 31.4) NA
ROC statistic 0.769 (0.76 to 0.778) NA
Pancreas cancer
D statistic 2.235 (2.126 to 2.345) 2.225 (2.119 to 2.33)
R2 (%) 54.4 (52 to 56.8) 54.2 (51.8 to 56.5)
ROC statistic 0.865 (0.855 to 0.875) 0.857 (0.847 to 0.867)
Prostate cancer
D statistic NA 2.252 (2.219 to 2.285)
R2 (%) NA 54.8 (54 to 55.5)
ROC statistic NA 0.895 (0.893 to 0.897)
Renal tract cancer
D statistic 2.005 (1.923 to 2.086) 2.234 (2.181 to 2.287)
R2 (%) 49 (46.9 to 51) 54.4 (53.2 to 55.5)
ROC statistic 0.851 (0.843 to 0.859) 0.863 (0.858 to 0.867)
Uterine cancer
D statistic 1.758 (1.677 to 1.839) NA
R2 (%) 42.5 (40.2 to 44.7) NA
ROC statistic 0.828 (0.819 to 0.837) NA
Notes on understanding validation statistics.
Discrimination is the ability of the risk prediction model to differentiate between patients who experience a admission event during the study
and those who do not. This measure is quantified by calculating the area under the receiver operating characteristic curve (ROC) statistic;
where a value of 1 represents perfect discrimination.
The D statistic is also a measure of discrimination which is specific to censored survival data. As with the ROC, higher values indicate better
discrimination.
R2 measures explained variation and higher values indicate more variation is explained.
NA, not applicable.
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since that would require (1) consideration of the
balance of risk/beneﬁt for an individual and their
choice and (2) cost-effectiveness analyses which are
outside the scope of this study. We have, however, pro-
vided analyses using the top 10% of absolute risk as a
threshold of risk which can be used to help inform
future analyses. Sensitivity is important as it is a measure
of how well the algorithm performs in ﬁnding cases that
might be suitable for intervention. If the risk threshold
is set too high, then the sensitivity will be low and a
large number of patients at increased risk of cancer will
be ‘missed’ by the algorithm. Although a high-risk
threshold is likely to result in a higher positive predictive
value which means a higher proportion of those identi-
ﬁed are likely to go on to develop cancer over the next
10 years. A lower risk threshold would have higher sensi-
tivity but could lead to unnecessary interventions and
anxiety in people who will not develop cancer over
10 years. So, at the population level, there is a balance to
be struck between the sensitivity and positive predictive
value of the score which depends on the risk threshold
selected, resources available; likely risks and beneﬁts of
the interventions and the chance that patients might
become anxious about being classiﬁed as ‘high risk’.
Methodological considerations
The methods to derive and validate these models are
the same as for a range of other clinical risk prediction
tools derived from the QResearch database.19 80–83 The
strengths and limitations of the approach have already
been discussed in detail21 80 83–86 including information
on multiple imputation of missing data. In summary, key
strengths include size, duration of follow-up, representa-
tiveness, and lack of selection, recall and respondent
bias. UK general practices have good levels of accuracy
and completeness in recording clinical diagnoses and
prescribed medications.87 We think our study has good
face validity since it has been conducted in the setting
where the majority of patients in the UK are assessed,
treated and followed up. Our database has linked hos-
pital, mortality and cancer records for nearly all patients
and is therefore likely to have picked up the majority of
cancer diagnoses thereby minimising ascertainment
bias. We excluded patients without a valid deprivation
score since this group may represent a more transient
population where follow-up could be unreliable or
unrepresentative. Their deprivation scores are unlikely
to be missing at random so we did not think it would be
appropriate to impute them.
The present validation has been carried out on a com-
pletely separate set of practices and individuals to those
which were used to develop the score although the prac-
tices all use the same GP clinical computer system
(EMIS—the computer system used by 55% of UK GPs).
An independent validation study would be a more strin-
gent test and should be carried out, but when such
Table 9 Classification statistics for each algorithm in the validation cohort based on the top 10% of patients at highest
predicted risk of each cancer in women
Type of cancer
Cut-off 10 year
risk (top 10%) Sensitivity (%) Specificity (%)
Observed risk
at 10 years (%)
Blood cancer 1.48 38.1 90.1 1.88
Bowel cancer 2.04 45.5 90.3 2.97
Breast cancer 3.40 27.5 90.2 4.42
Gastro-oesophageal cancer 0.65 53.3 90.1 1.07
Lung cancer 1.43 67.3 90.2 3.91
Oral cancer 0.17 42.3 90.0 0.32
Ovarian cancer 0.70 28.1 90.0 0.87
Pancreas cancer 0.50 50.0 90.0 0.76
Renal tract cancer 0.94 46.6 90.1 1.37
Uterine cancer 0.72 42.6 90.1 1.20
Table 10 Classification statistics for each algorithm in the validation cohort based on the top 10% of patients at highest
predicted risk of each cancer in men
Type of cancer
Cut-off 10 year
risk (top 10%) Sensitivity (%) Specificity (%)
Observed risk at
10 years (%)
Blood cancer 1.96 40.0 90.1 2.75
Bowel cancer 2.82 50.6 90.2 4.20
Lung cancer 2.73 66.6 90.3 6.17
Gastro-oesophageal 1.34 52.9 90.1 2.27
Oral cancer 0.33 46.3 90.0 0.70
Pancreas cancer 0.52 49.3 90.0 0.86
Prostate cancer 5.89 56.2 90.4 8.42
Renal tract cancer 2.54 50.4 90.2 3.80
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independent studies have examined other risk algo-
rithms,85 86 88 89 they have demonstrated comparable
performance compared with the validation in the
QResearch database.19 80 84 We (or another academic
team) intend to conduct a separate validation on an
independent database using a different clinical system
(CPRD) as part of a separate project.
Other limitations of our study include the lack of
formal adjudication of cancer diagnoses, information
bias, and potential for bias due to missing data.
However, we think our ascertainment of cancer is likely
to be high given the combination of the four data
sources and the similarity between our rates and those
published by the Ofﬁce for National Statistics.11 While
we acknowledge that there may be discrepancies
between self-reported features (such as number of cigar-
ettes smoked), the information recorded on the GP
record has a face validity as it is still predictive of rele-
vant outcomes, exhibits a ‘dose-response’ relationships
(with higher doses being associated with increased
cancer risks) and similar to HRs from the published lit-
erature as we describe above. We have also only based
behavioural variables (for smoking and alcohol) on a
simple assessment of current exposure rather than more
complex measures reliant on recall of past exposure
which would be less reliable.
We measured family history of cancer based on infor-
mation which may have been recorded opportunistically
rather than systematically. Patients with a positive family
history of cancer may be more likely to report this to
their GP and for this to be recorded and we have
assumed that where no positive family history is
recorded then the patients has a negative family history
which will lead to some misclassiﬁcation. Also, there is
no Read code to record family history of some types of
cancer (eg, pancreatic cancer) so we were unable to
include this in our list of predictor variables as this infor-
mation is not captured in coded form and available on
the QResearch database. Overall, the recording of family
history is therefore likely to be subject to both ascertain-
ment and recording bias. However, it is likely that the
recording of family history will improve over time par-
ticularly if (1) clinicians can be prompted to ask for this
information by the use of structured clinical templates
which can be offered to the clinician for use during the
consultation or if (2) patients can record this informa-
tion directly once they are able to access their medical
record electronically.
Genetic information is likely to be important in a full
assessment of cancer risk although the information is
not currently routinely recorded in electronic health
records. Genetic information cannot therefore be used
Figure 6 Showing the mean predicted risks and observed risks at 10 years by tenth of predicted risk applying each algorithm to
all women in the validation cohort.
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either to derive or validate a new score using large rep-
resentative UK clinical databases. The lack of routinely
available genetic results would also cause practical pro-
blems in implementing a tool dependent on such vari-
ables into clinical practice. Previous studies examining
the beneﬁts of adding genetic variations to risk assess-
ment tools have shown only modest improvements in
the predictive power. For example adding genetic
variant information to the Gail Breast Cancer Risk assess-
ment tool only increased the ROC value from 0.58 to
0.62.90 The ROC value for the breast cancer algorithm
based on clinical data in our study was 0.76 which is sig-
niﬁcantly higher than the ROC value of 0.62 reported
for the generic variant of the Gail model.90
A recent study by Tomasetti et al 91 concluded that
“only a third of the variation in cancer risk among tissues
is attributable to environmental factors or inherited pre-
dispositions. The majority is due to ‘bad luck’, that is,
random mutations arising during DNA replication in
normal, noncancerous stem cells”. Our study focuses on
methods to predict absolute risk of cancer taking account
of the individual’s age, sex, ethnicity, lifestyle, family
history and comorbidities. We found that our models
explained well over 33% of the variation in cancer risk
for 9 of the 11 cancers studied as shown by the R2 values
presented in table 8. This would tend to refute the
hypothesis by Tomasetti et al 91 that only a third of the
variation in cancer risk among tissues is attributable to
environmental factors or inherited predispositions with
the remainder being due to random mutations for the
majority of cancers. However, our models only explained
22% of the variation for breast cancer and 29% for
ovarian cancer which would support it.
The prediction models in our study have been derived
from routinely recorded electronic health data using
variables which are accessible in everyday practice in
order that they can be applied in real world clinical set-
tings to identify high-risk patients for further screening
or prevention. Overall the validation statistics indicate
that performance of all the algorithms is either good
(breast, oral and ovarian cancers have ROC values
0.76–0.79); very good (blood, bowel, gastro-oesophageal,
pancreas prostate, renal, uterine cancers have ROC
values of 0.80 to 0.89) or excellent (lung cancer has an
ROC value >0.9). Our prediction models have included
clinical and lifestyle variables (such as age/sex/ethni-
city/coexisting illnesses/smoking/alcohol and medica-
tion). They also include family history which was a
signiﬁcant predictor for six cancers (prostate, breast,
bowel, blood, lung, ovarian). While there is clearly a
Figure 7 Showing the mean predicted risks and observed risks at 10 years by tenth of predicted risk applying each algorithm to
all men in the validation cohort.
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difference between family history information and a
genetic sample, family history does reﬂect genetic
factors and is routinely recorded in general practice set-
tings. It would be impractical, both from a cost and gov-
ernance perspective to undertake genetic tests on all
patients so that this information could be included in
derivation of the models. It would also be impractical to
require genetic information to be available routinely for
when the scores are applied. It would be possible,
however, to use the QCancer 10 year risk tool to identify
a subset of high-risk patients for whom further genetic
testing might be warranted and to quantify the level of
absolute risk to help inform patient choice.
The QCancer 10 year risk algorithms have been devel-
oped using linked data from general practices in
England and some of them (breast, gastro-oesophageal,
lung, oral, pancreatic, prostate and renal tract) include a
postcode related deprivation score (Townsend score).
We included the Townsend score in the algorithms since
there were clear relationships between deprivation and
risk of some cancers which is captured by this variable.
If we omitted it, it would tend to under-estimate cancer
risk in patients from deprived areas for most cancers
except breast cancer and renal cancer in women and
prostate cancer in men, where the risk may be slightly
over-estimated. In terms of international use of these
algorithms where the Townsend score is not available a
locally relevant deprivation score could be constructed
or adapted for the relevant country to have a range
between −7 (most afﬂuent) and +11 (most deprived) to
correspond to the range of Townsend scores which
could be used instead (subject to local validation). For
other predictor variables such as age, smoking, alcohol,
family history, prior cancer, then we have compared the
magnitude of the HRs to other international studies and
found them to be similar in direction and magnitude
(see Comparison with literature). This would tend to
support the utility and face validity of the algorithms
outside the UK although best practice would be that
they are externally and independently validated in the
settings where they would be used to ensure they are
appropriately calibrated and have good discrimination.
Lastly changes in environmental factors may occur
over time and this underlines the need to update the
prediction algorithms on an ongoing basis as has been
carried out with QRISK292 cardiovascular score and
other related prediction scores.93 Regular updates, with
a moving time window, will also help ensure that the
algorithms will beneﬁt from improvements in the scope
and quality of the underlying database which is likely to
occur over time. This is an important strength of using
routine databases for the development of risk prediction
algorithms that is not feasible with prospective study
cohorts that are assembled at one point in time.
Figure 8 Showing the web
calculator for an example patient.
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Clinical implications
The algorithms have been designed to work in a
primary care setting, making use of information which is
already recorded on the GP clinical computer system.
The algorithms can be integrated into the clinical
computer system alongside similar algorithms which
already quantify risk of other clinical conditions in every-
day clinical practice such as QRISK2,19 QDiabetes,80
QStroke,94 QFracture,81 QThrombosis,83 QBleed95 and
QAdmissions.12 They can be used in ‘batch process’
mode to generate a list of patients at high risk of each
cancer for further assessment or they could be used
within the consultation. For example, policy makers and
commissioners are likely to want to use the tumour site
speciﬁc algorithms in ‘batch mode’ to risk stratify popu-
lations to better target screening programmes.
To indicate the potential value of using the QCancer
tool for identifying a high-risk population for screening
compared to an approach based on risk factors alone,
we calculated the sensitivity and predictive values for
lung cancer in heavy and moderate smokers. In the val-
idation data set for women there were 3007 lung cancer
cases over 10 years, and 812 occurred in moderate/
heavy smokers (9.3% of cohort) giving a sensitivity of
27%, this contrasts with a sensitivity of 67% for the top
10% of women at highest predicted risk of lung cancer
using the QCancer score (table 9). In men the corre-
sponding sensitivity values are 22% in moderate/heavy
smokers compared with 67% using QCancer (table 10).
So QCancer is better at identifying future lung cancer
cases than an approach targeting moderate/heavy
smokers would be. Further work would be needed to
determine any risk thresholds for screening, which as we
state in the paper would require cost-effectiveness ana-
lyses which are outside the scope of this study and con-
sideration of available resources and impacts on
patients.
The algorithms could help inform the discussions
between doctor and patient within the consultation
regarding the future risk of cancer associated with exist-
ing diagnoses (such as the risk of bowel cancer among
patients with ulcerative colitis); prior cancers (which
might indicate an increased risk of a second primary
cancer); family history of cancer (where additional
screening may be justiﬁed) or lifestyle related variables
(such as BMI, smoking and alcohol intake which can be
moderated). For example, the doctor could use the algo-
rithms to assess the patient’s 10 year risk of cancer to
highlight the higher risk associated with heavy or moder-
ate smoking compared with that for lighter smokers or
ex-smokers. Currently there is no easy to use widely avail-
able calculator, such as that described in this paper,
which will allow a patient to quantify their absolute risk
of getting different types of cancer taking account of
their age, sex, family history and other risk factors such
as alcohol consumption and smoking status. While iden-
tifying effective interventions to reduce alcohol intake or
increase smoking cessation remains a challenge, there is
evidence96 that physician advice has some effect on
smoking cessation rates albeit small and that brief
alcohol interventions in primary care populations can
reduce alcohol consumption.97 It is possible that provid-
ing patients with information on how these factors inﬂu-
ence their personal cancer risk might have an additional
impact on smoking and alcohol consumption. There is
also some evidence to support the use of biomedical risk
assessment feedback such as ‘lung age’ to increase rates
of smoking cessation98 which suggests that patients may
respond to information presented in an accessible
format.
As another example, the doctor and patient could also
review treatments such as the use of HRT in a woman at
higher risk of breast cancer due to other factors such as
family history. However, if a patient presents with poten-
tial symptoms of cancer such as appetite loss or haema-
turia the existing QCancer scores we developed
previously3–10 would be more suitable for assessing
current cancer risk and informing decisions regarding
further investigation and referral.
CONCLUSION
We have developed and validated a new set of risk pre-
diction models which quantify the absolute risk of 11
common cancers in men and women. They can be used
to identify patients at high risk of cancers for prevention
or further assessment. Following external validation and
cost-effectiveness assessments, the algorithms could be
integrated into GP clinical computer systems and used
to identify high-risk patients for prevention and
screening.
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